

**IN THE CLAIMS:**

**Please amend the claims as follows:**

*Sub C1*

20. (Twice Amended) An isolated haemopoietin receptor comprising:

- (i) an amino acid sequence having at least about 90% identity to the amino acid sequence set forth in any one of SEQ ID NO: 13, 15, 17, 19, 25 and 29;
- (ii) an amino acid sequence encoded by a nucleotide sequence having at least about 85% identity to the nucleotide sequence set forth in any one of SEQ ID NO: 12, 14, 16, 18, 24 and 28; or
- (iii) an amino acid sequence encoded by a nucleotide sequence which hybridizes under high stringency conditions to the nucleotide sequence set forth in any one of SEQ ID NO: 12, 14, 16, 18, 24 and 28;

*f*

wherein said receptor further comprises the amino acid motif:

Trp Ser Xaa Trp Ser (SEQ ID NO: 1)

wherein Xaa is any amino acid.

*Sub C3*

22. (Twice Amended) The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence set forth in SEQ ID NO: 13.

*f2*

23. (Twice Amended) The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence set forth in SEQ ID NO: 15.

24. (Twice Amended) The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence set forth in SEQ ID NO: 17.

25. (Twice Amended) The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence set forth in SEQ ID NO: 19.

*sub G3 cont.*  
*J2*  
*cont*

26. (Twice Amended) The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence set forth in SEQ ID NO: 25.

27. (Twice Amended) The isolated haemopoietin receptor according to claim 21 comprising the amino acid sequence set forth in SEQ ID NO: 29.

*sub G4*

35. (Amended) An isolated haemopoietin receptor comprising an amino acid sequence having at least about 90% identity to the amino acid sequence set forth in any one of SEQ ID NO: 13, 15, 17, 19, 25 and 29, wherein said receptor further comprises the amino acid motif:  
Trp Ser Xaa Trp Ser (SEQ ID NO: 1)

wherein Xaa is any amino acid.

*sub G5*

37. (Amended) An isolated haemopoietin receptor comprising an amino acid sequence encoded by a nucleotide sequence having at least about 85% identity to the nucleotide sequence set forth in any one of SEQ ID NO: 12, 14, 16, 18, 24 and 28, wherein said receptor further comprises the amino acid motif:

Trp Ser Xaa Trp Ser (SEQ ID NO: 1)

wherein Xaa is any amino acid.

*sub G6*  
*J5*

39. (Amended) An isolated haemopoietin receptor comprising an amino acid sequence encoded by a nucleotide sequence which hybridises under high stringency conditions to the nucleotide sequence set forth in any one of SEQ ID NO: 12, 14, 16, 18, 24 and 28, wherein said receptor further comprises the amino acid motif:

Trp Ser Xaa Trp Ser (SEQ ID NO: 1)

wherein Xaa is any amino acid.

*J6*

41. (Amended) An isolated haemopoietin receptor according to claim 39 wherein said high stringency conditions comprise from at least about 31% v/v to at least about 50% v/v formamide

*36*  
*cont*  
for hybridisation, and from at least about 0.01M to at least about 0.15M salt at about 42°C for washing.

*37*  
43. (Amended) An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO: 13.

44. (Amended) An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO: 15.

45. (Amended) An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO: 17.

46. (Amended) An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO: 19.

47. (Amended) An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO: 25.

48. (Amended) An isolated haemopoietin receptor comprising the amino acid sequence set forth in SEQ ID NO: 29.

#### REMARKS

In the Final Action dated August 28, 2001, claims 20-27 and 35-48 are pending and under consideration. Claims 20-27 and 35-48 are rejected under 35 U.S.C. §101 as allegedly not supported by either a specific and substantial asserted utility or a well-established utility. Claims 20-27 and 35-48 are also rejected under 35 U.S.C. §112, first paragraph, allegedly because the specification fails to teach those skilled in the art how to use the invention as claimed. Claims 20-27 and 35-41 are further rejected under 35 U.S.C. §112, second paragraph, as allegedly indefinite. In addition, claims 20, 22-27, 37, 39 and 43 are objected to for certain informalities.